Niels Abildgaard
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 114
- Oncology top 1%
- Bone health and treatments 34
- Cancer Treatment and Pharmacology 32
- Peptidase Inhibition and Analysis 15
- Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 16
- Chronic Lymphocytic Leukemia Research 12
- Hepatology top 5%
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 19
- Amyloidosis: Diagnosis, Treatment, Outcomes 12
- Co-authors
- Magne BørsetAnders SundanLene HeickendorffJohan Lanng NielsenCarina SeidelIngemar TuressonNiels Frost AndersenAnders Waage
- Cited by
- HematologyOncologyGenetics
- Journals
- European Journal Of Haematology (25 papers)Blood (19 papers)British Journal of Haematology (11 papers)
- Partner nations
- DenmarkNorwayUnited States
In The Last Decade
Niels Abildgaard
159 papers receiving 3.6k citations
Peers
Comparison fields: 5 of 116
- Hematology 2.2k
- Oncology 1.8k
- Genetics 441
- Hepatology 217
- Molecular Biology 1.5k
Countries citing papers authored by Niels Abildgaard
This map shows the geographic impact of Niels Abildgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niels Abildgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niels Abildgaard more than expected).
Fields of papers citing papers by Niels Abildgaard
This network shows the impact of papers produced by Niels Abildgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niels Abildgaard. The network helps show where Niels Abildgaard may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Niels Abildgaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 3 | |
| 9 | 2022 | 2 | |
| 10 | 2022 | 8 | |
| 11 | 2021 | 11 | |
| 12 | 2021 | 5 | |
| 13 | 2021 | 18 | |
| 14 | 2020 | 14 | |
| 15 | 2018 | 31 | |
| 16 | 2018 | 7 | |
| 17 | 2017 | 37 | |
| 18 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 2017 | 0 |
| 19 | 2010 | 14 | |
| 20 | A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity | 2008 | 16 |
About Niels Abildgaard
Niels Abildgaard is a scholar working on Hematology, Oncology, Genetics, Cancer Research and Molecular Biology, having authored 168 papers that have together received 3.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (114 papers), Bone health and treatments (34 papers), Cancer Treatment and Pharmacology (32 papers), Protein Degradation and Inhibitors (19 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Peptidase Inhibition and Analysis (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers). The work is most often cited by research in Hematology (2.2k citations), Oncology (1.8k citations), Genetics (441 citations), Hepatology (217 citations) and Molecular Biology (1.5k citations). Niels Abildgaard has collaborated with scholars based in Denmark, Norway and United States. Frequent co-authors include Magne Børset, Anders Sundan, Lene Heickendorff, Johan Lanng Nielsen, Carina Seidel, Ingemar Turesson, Niels Frost Andersen, Anders Waage, Peter Gimsing and Øyvind Hjertner. Their work appears in journals such as European Journal Of Haematology, Blood, British Journal of Haematology, Leukemia and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.